Aviva’s AbCellera Biologics ABCL Stock Holding History

Aviva’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-154,325	Closed	-$1.53M	–	998
2022 Q3	$1.53M	Buy	+154,325	New	+$1.69M	0.01%	775

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aviva's ABCL Position: Q4 2022 in Review

Aviva sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 154,325 shares — an estimated $1.53M sold.

Aviva first reported a position in ABCL in Q3 2022 and held it in 1 quarter. The position peaked at $1.53M in Q3 2022. 201 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

Aviva reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
Aviva sold 154,325 AbCellera Biologics shares in Q4 2022, an estimated $1.53M.
Aviva first reported a position in AbCellera Biologics in Q3 2022 and held it in 1 quarter.
Aviva's AbCellera Biologics position peaked at $1.53M in Q3 2022.
201 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on Aviva's 13F filing for Q4 2022, filed 9 Feb 2023.